Sarepta Therapeutics to Present Company Overview at Upcoming Conferences

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today announced that management is scheduled to participate in fireside chats at the following investor conferences in February. Chris Garabedian, Sarepta’s president and chief executive officer, will be the presenter.

  • 4th Annual Leerink Partners Global Healthcare Conference in New York, NY on Wednesday, February 11, at 10:15 a.m. EST.
  • 2015 RBC Capital Markets Global Healthcare Conference in New York, NY on Tuesday, February 24, at 11:30 a.m. EST.

The presentations will be webcast live on the investor relations section of the Sarepta Therapeutics website at www.sarepta.com and will be archived under the events and presentations section following each presentation for 90 days.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sarepta.com.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our web site at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Contacts:

Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
iestepan@sarepta.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.